Apixaban (Eliquis)

Trade Name : ELIQUIS

E.R. Squibb & Sons, L.L.C.

TABLET, FILM COATED

Strength 2.5 mg/1

APIXABAN Factor Xa Inhibitor [EPC],Factor Xa Inhibitors [MoA]

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Apixaban (Eliquis) which is also known as ELIQUIS and Manufactured by E.R. Squibb & Sons, L.L.C.. It is available in strength of 2.5 mg/1 per ml. Read more

Apixaban (Eliquis) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials. Click to know price. Read less

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Inquire directly from our website and get 5% off on any medicine!

About GNH

No data

Warnings and Precautions, Increased Risk of Thrombosis in Patients with Triple Positive Antiphospholipid Syndrome u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a011/2019

(A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS
Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant .
(B) SPINAL/EPIDURAL HEMATOMA
Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:
Arrayn- [see ]
Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary .
Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated .
WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA
See full prescribing information for complete boxed warning.
(B) SPINAL/EPIDURAL HEMATOMA: Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. n

ELIQUIS is a factor Xa inhibitor indicated:

(1.3n- 1.4n- 1.5)

No data

Arrayn- Array
Arrayn- Array
Arrayn- Array
Arrayn- Array

No data

u2022
(3)

ELIQUIS is contraindicated in patients with the following conditions:

No data

The following clinically significant adverse reactions are discussed in greater detail in other sections of the prescribing information.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Most common adverse reactions (>1%) are related to bleeding. n
Arrayn- www.fda.gov/medwatch

Apixaban is a substrate of both CYP3A4 and P-gp. Inhibitors of CYP3A4 and P-gp increase exposure to apixaban and increase the risk of bleeding. Inducers of CYP3A4 and P-gp decrease exposure to apixaban and increase the risk of stroke and other thromboembolic events.

(2.5n- 7.1n- 12.3)
(7.2n- 12.3)

No data

Pregnancy:
Lactation:
Severe Hepatic Impairment:

Overdose of ELIQUIS increases the risk of bleeding .
In controlled clinical trials, orally administered apixaban in healthy subjects at doses up to 50 mg daily for 3 to 7 days (25u00a0mg twice daily for 7 days or 50 mg once daily for 3 days) had no clinically relevant adverse effects.
In healthy subjects, administration of activated charcoal 2 and 6 hours after ingestion of a 20-mg dose of apixaban reduced mean apixaban AUC by 50% and 27%, respectively. Thus, administration of activated charcoal may be useful in the management of ELIQUIS overdose or accidental ingestion. An agent to reverse the anti-factor Xa activity of apixaban is available.

ELIQUIS (apixaban), a factor Xa (FXa) inhibitor, is chemically described as 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1-pyrazolo[3,4-]pyridine-3-carboxamide. Its molecular formula is CHNO, which corresponds to a molecular weight of 459.5. Apixaban has the following structural formula:
Apixaban is a white to pale-yellow powder. At physiological pH (1.2-6.8), apixaban does not ionize; its aqueous solubility across the physiological pH range is ~0.04 mg/mL.
ELIQUIS tablets are available for oral administration in strengths of 2.5 mg and 5 mg of apixaban with the following inactive ingredients: anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. The film coating contains lactose monohydrate, hypromellose, titanium dioxide, triacetin, and yellow iron oxide (2.5 mg tablets) or red iron oxide (5 mg tablets).

No data

Carcinogenesis:
Mutagenesis:
in vitro
in vivo/in vitro
in vivo
Impairment of Fertility:
Apixaban administered to female rats at doses up to 1000 mg/kg/day from implantation through the end of lactation produced no adverse findings in male offspring (F1 generation) at doses up to 1000 mg/kg/day, a dose resulting in exposure to unbound apixaban that is 5 times the human exposure. Adverse effects in the F1-generation female offspring were limited to decreased mating and fertility indices at u2265200 mg/kg/day (a dose resulting in exposure to unbound apixaban that is u22655 times the human exposure).

No data

No data

Advise patients to read the FDA-approved patient labeling (Medication Guide).
Advise patients of the following:

Marketed by:Bristol-Myers Squibb CompanyPrinceton, New Jersey 08543 USAandPfizer IncNew York, New York 10017 USA
[PRINT CODES]

ELIQUISn n- (apixaban)n- tablets
What is the most important information I should know about ELIQUIS?
What is ELIQUIS?
ELIQUIS is a prescription medicine used to:
It is not known if ELIQUIS is safe and effective in children.
Who should not take ELIQUIS?
Do not take ELIQUIS if you:
What should I tell my doctor before taking ELIQUIS?
Before you take ELIQUIS, tell your doctor if you:
Tell all of your doctors and dentists that you are taking ELIQUIS. They should talk to the doctor who prescribed ELIQUIS for you, before you have surgery, medical or dental procedure.
Tell your doctor about all the medicines you take, includingn- What is the most important information I should know about ELIQUIS?
Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.
How should I take ELIQUIS?
What are the possible side effects of ELIQUIS?
Tell your doctor if you have any side effect that bothers you or that does not go away.
These are not all of the possible side effects of ELIQUIS. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store ELIQUIS?
Store ELIQUIS at room temperature between 68u00b0F to 77u00b0F (20u00b0C to 25u00b0C).
Keep ELIQUIS and all medicines out of the reach of children.
General Information about ELIQUIS
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ELIQUIS for a condition for which it was not prescribed. Do not give ELIQUIS to other people, even if they have the same symptoms that you have. It may harm them.
If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about ELIQUIS that is written for health professionals.
For more information, call 1-855-354-7847 (1-855-ELIQUIS) or go to www.ELIQUIS.com.
What are the ingredients in ELIQUIS?
Active ingredient: apixaban.
Inactive ingredients: anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. The film coating contains lactose monohydrate, hypromellose, titanium dioxide, triacetin, and yellow iron oxide (2.5 mg tablets) or red iron oxide (5 mg tablets).
This Medication Guide has been approved by the U.S. Food and Drug Administration.n n n
Marketed by:Bristol-Myers Squibb CompanyPrinceton, New Jersey 08543 USAandPfizer IncNew York, New York 10017 USA
All other trademarks are property of their respective companies.

See section for a complete list of available packages of ELIQUIS.
60 TabletsNDC 0003-0893-21ELIQUISn (apixaban) tablets2.5 mgDISPENSE WITH MEDICATION GUIDERx onlyBristol-Myers SquibbPfizer

60 TabletsNDC 0003-0894-21ELIQUISn (apixaban) tablets5 mgDISPENSE WITH MEDICATION GUIDERx onlyBristol-Myers SquibbPfizer

ELIQUISn (apixaban) tabletsNDC 0003-3764-7430-Day Starter PackRx onlyn
30-Day Starter Pack5 mg per tabletfor the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)DISPENSE WITH MEDICATION GUIDEPlease see the enclosed full Prescribing Information, including Boxed Warnings and Medication Guide
Contains Two Wallets74 tablets, 5 mg per tablet
Wallet 1: Days 1-14Start with Wallet 1
Wallet 2: Days 15-30Switch to Wallet 2 on Day 15
Bristol-Myers SquibbPfizer

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64020 Products

GNH India Brings to over 64036 Product SKUs from India all at 1 place with easy access and global deliveries.

US NDC

71246 Products

GNH India Brings to over 71252 Product SKUs from India all at 1 place with easy access and global deliveries.

Canadian DIN

51046 Products

GNH India Brings to over 51047 Product SKUs from India all at 1 place with easy access and global deliveries.

Swiss Drugs

150 Products

GNH India Brings to over 150 Product SKUs from India all at 1 place with easy access and global deliveries.

NZ Drugs

13296 Products

GNH Brings to over 13298 Product SKUs from India all at 1 place with easy access and global deliveries.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Get Price

Apixaban (Eliquis)

Trade Name : ELIQUIS

TABLET, FILM COATED

Delivery Process

Product information is meant for

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

Packaging and Delivery

About GNH

Similar Products

Desogestrel And Ethinyl Estradiol (Emoquette)

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Fluoxetine Hydrochloride (Fluoxetine)

Metoprolol Succinate (Metoprolol Succinate)

Losartan Potassium (Losartan Potassium)

Browse Our Services And Processes

Disclaimer

Browse from other international pharmaceuticals

General

US NDC

Canadian DIN

Swiss Drugs

NZ Drugs

FAQ

Can’t find what
you’re looking for?

COMPANY

SERVICES

QUICK LINKS

CONTACT US

Apixaban (Eliquis)

Trade Name : ELIQUIS

TABLET, FILM COATED

Delivery Process

Product information is meant for

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

Packaging and Delivery

About GNH

Similar Products

Desogestrel And Ethinyl Estradiol (Emoquette)

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Fluoxetine Hydrochloride (Fluoxetine)

Metoprolol Succinate (Metoprolol Succinate)

Losartan Potassium (Losartan Potassium)

Browse Our Services And Processes

Disclaimer

Browse from other international pharmaceuticals

General

US NDC

Canadian DIN

Swiss Drugs

NZ Drugs

FAQ

Can’t find what you’re looking for?

COMPANY

SERVICES

QUICK LINKS

CONTACT US

Can’t find what
you’re looking for?